Reversible PEGylation of peptide YY3‐36 prolongs its inhibition of food intake in mice
Authors:
- Haim TsuberyHTHaim Tsubery
- Marina MironchikMMMarina Mironchik
- Menachem RubinsteinMRMenachem Rubinstein
- Mati FridkinMFMati Fridkin
- 31 March 2005
- journal article
- Published by Wiley in FEBS Letters
- Vol. 579 (11) , 2439-2444
Abstract
Administration of peptide YY3‐36 (PYY3‐36) to fasting humans or mice shortly before re‐feeding effectively reduced their food intake, but PYY3‐36 exhibited a functional half‐life of only ∼3 h. Attachment of poly(ethylene glycol) to proteins and peptides (PEGylation) prolongs their half‐life in vivo, but completely inactivated PYY3‐36. We developed a reversibly PEGylated PYY3‐36 derivative by coupling it to a 40 kDa PEG through a spontaneously cleavable linker. The resulting conjugate (PEG40–FMS–PYY3‐36) gradually released unmodified PYY3‐36 in vivo, exhibiting an eightfold increase in its functional half‐life, to ∼24 h. This long‐acting PYY3‐36 pro‐drug may serve as an effective means for controlling food intake in humans.Keywords
This publication has 23 references indexed in Scilit:
- Comparison of the inhibitory effects of PYY(3-36) and PYY(1-36) on gastric emptying in ratsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2004
- Does gut hormone PYY3–36 decrease food intake in rodents?Nature, 2004
- Inhibition of Food Intake in Obese Subjects by Peptide YY3–36New England Journal of Medicine, 2003
- Peptide and protein PEGylationBiomaterials, 2001
- A new approach for prolonging the half-life of peptides, proteins and low-molecular-weight drugs in vivoDrugs of the Future, 2001
- Drug Delivery Systems Employing 1,4- or 1,6-Elimination: Poly(ethylene glycol) Prodrugs of Amine-Containing CompoundsJournal of Medicinal Chemistry, 1999
- Interacting Appetite-Regulating Pathways in the Hypothalamic Regulation of Body WeightEndocrine Reviews, 1999
- The conjugation of proteins with polyethylene glycol and other polymersAdvanced Drug Delivery Reviews, 1993
- The clinical efficacy of poly(ethylene glycol)-modified proteinsJournal of Controlled Release, 1990
- The preparation and properties of novel reversible polymer‐protein conjugates 2‐ω‐Methoxypolyethylene (5000) glycoxymethylene‐3‐methylmaleyl conjugates of plasminogen activatorsFEBS Letters, 1987